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Cocaine is thought to be addictive because it elevates dopamine levels in the striatum, reinforcing drug-seeking habits. Cocaine
also elevates dopamine levels in the hippocampus, a structure involved in contextual conditioning as well as in reward function.
Hippocampal dopamine promotes the late phase of consolidation of an aversive step-down avoidance memory. Here, we examined
the role of hippocampal dopamine function in the persistence of the conditioned increase in preference for a cocaine-associated
compartment. Blocking dorsal hippocampal D1-type receptors (D1Rs) but not D2-type receptors (D2Rs) 12 h after a single training
trial extended persistence of the normally short-lived memory; conversely, a general and a specific phospholipase C-coupled D1R
agonist (but not a D2R or adenylyl cyclase-coupled D1R agonist) decreased the persistence of the normally long-lived memory
established by three-trial training. These effects of D1 agents were opposite to those previously established in a step-down
avoidance task, and were here also found to be opposite to those in a lithium chloride-conditioned avoidance task. After returning to
normal following cocaine injection, dopamine levels in the dorsal hippocampus were found elevated again at the time when
dopamine antagonists and agonists were effective: between 13 and 17 h after cocaine injection. These findings confirm that, long after the
making of a cocaine–place association, hippocampal activity modulates memory consolidation for that association via a dopamine-
dependent mechanism. They suggest a dynamic role for dorsal hippocampal dopamine in this late-phase memory consolidation
and, unexpectedly, differential roles for late consolidation of memories for places that induce approach or withdrawal because of
a drug association.
Neuropsychopharmacology (2014) 39, 1645–1653; doi:10.1038/npp.2014.11; published online 12 February 2014
























































The addicted brain differs from the non-addicted brain as a
function of two forms of neuroplasticity that are important
for addiction theory: neuroadaptations resulting from the
pharmacological impact of the drug on the brain and
synaptic changes that reflect the memory trace for the drug
experience (Berke and Hyman, 2000; Hyman et al, 2006).
Neuroadaptations that are caused by repeated passive
exposure to the drug itself have been widely studied
(Nestler, 1992; Lüscher and Malenka, 2011), but there are
further changes in brain function that reflect the memory
of drug experience. These further brain changes are seen in
animals that self-administer the drug, but are absent in
animals that have passively received ‘yoked’ injections of
the same drug at the same dose and temporal pattern
(Wang et al, 2005; You et al, 2007, 2008; Chen et al, 2008;
Caillé et al, 2009). Here, we were concerned with brain
changes involved in the consolidation of the memory for
drug–environment association established by Pavlovian
conditioning.
Much of the interest in the neuroplasticity associated with
cocaine addiction has been focused on the ventral tegmental
dopamine neurons (Bonci and Malenka, 1999; Saal et al,
2003) and their projection targets in the nucleus accumbens
(Nestler, 1992; Hyman et al, 2006; Kalivas, 2009).
Self-administered cocaine elevates dopamine levels there
(Pettit et al, 1990; Wise et al, 1995), and the rewarding
effects of self-administered cocaine are attenuated or
blocked by lesions or infusion of dopamine antagonists
into this area. Cocaine (Ikemoto, 2003) and dopamine
agonists (Ikemoto and Goeders, 1998) are reinforcing
when injected into the medial portions of the ventral
striatum. However, while the striatum is thought to have the
major role in the establishment of instrumental response
habits (Everitt and Robbins, 2005), rats not only learn to
*Correspondence: Dr MF Barbano. Current address: National Institute
on Drug Abuse, Intramural Research Program, Neuronal Networks
Section, National Institutes of Health, 251 Bayview Boulevard, Baltimore,
MD 21224, USA, Tel: +1 443 740 2709, Fax: +1 443 740 2827,
E-mail: maria.barbano@nih.gov
Received 28 September 2013; revised 6 December 2013; accepted 13
January 2014; accepted article preview online 20 January 2014
Neuropsychopharmacology (2014) 39, 1645–1653
& 2014 American College of Neuropsychopharmacology. All rights reserved 0893-133X/14
www.neuropsychopharmacology.org
self-administer addictive drugs but they also learn to
approach and spend more time in the places where they
have experienced addictive drugs in the past. Such learning
is likely to implicate the hippocampal circuitry involved in
spatial and contextual learning (O’Keefe and Nadel, 1978;
Phillips and LeDoux, 1994). One such circuit may involve
the functional loops linking the ventral tegmental area
(VTA) and the hippocampus (Lisman and Grace, 2005; Luo
et al, 2011). Recent findings point to the dorsal hippo-
campus, and particularly to its dopaminergic inputs,
as important for the persistence of memory storage in
behaving rats (Rossato et al, 2009). This modulation is
mediated by dopamine (acting at D1-type receptors (D1Rs))
and brain-derived neurotrophic factor (BDNF) 12 h after
training (but not 0, 9, or 24 h after training), and is selective
for the maintenance, but not for the formation, of
fear-associated long-term memories (LTMs) (Bekinschtein
et al, 2007; Rossato et al, 2009). However, the mechanisms
by which a drug-related memory becomes persistent over
time remain to be elucidated. In the present study, we
explore the role of dorsal hippocampal dopamine in
modulating the persistence of memories for the association
between rewarding cocaine or aversive lithium chloride
(LiCl) and the experimental chamber in which the effects of
the drugs were experienced.
MATERIALS AND METHODS
See Supplementary Materials and methods’ for further
details.
Animals
A total of 949 male Sprague–Dawley rats (Facultad de
Ciencias Veterinarias, Argentina; and Charles River, Ra-
leigh, NC) were used. Groups of five rats each (weighting
around 200 g upon arrival at the laboratory) were housed in
a vivarium maintained on a reversed 12-h light–dark cycle
(lights off at 0630 hours) at a constant temperature of 23 1C.
Animal care was in strict accordance with institutional and
international standards (National Research Council, 2011;
NIDA Animal Care and Use Committee).
Drugs
Cocaine hydrochloride (Laboratorios Verardo y Cia.,
Buenos Aires, Argentina or NIDA intramural pharmacy,
Baltimore, MD), SCH 23390 hydrochloride, quinpirole
hydrochloride (Sigma-Aldrich, St Louis, MO), eticlopride
hydrochloride (Tocris Bioscience, Bristol, UK), LiCl (La-
boratorio Cicarelli, San Lorenzo, Argentina) were all
dissolved in sterile 0.9% physiological saline. SKF 38393
hydrochloride, SKF 83959 hydrobromide (Sigma-Aldrich),
and SKF 83822 hydrobromide (Tocris Bioscience) were
dissolved in sterile 0.9% physiological saline supplemented
with DMSO (10%, final concentration; Laboratorio Ernesto
van Rossum y Cia., Buenos Aires, Argentina). All the
antibodies, except for anti-phospho-ERK1/2 and anti-ERK1/
2 (Cell Signaling Technology, Beverly, MA), were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
Surgical and Intracerebral Infusion Procedures
Each rat was anesthetized with a mix of ketamine (85 mg/kg)
and xylazine (10 mg/kg), and placed on a stereotaxic frame.
The skull was exposed and leveled (flat skull, lambda, and
bregma at the same elevation). Either 22-G guide cannulae
for intracerebral infusions or CMA 11 microdialysis guide
cannulae (CMA, Helsingborg, Sweden) were bilaterally
implanted, aimed at the dorsal hippocampus (CA1 region).
The stereotaxic coordinates used were as follows: AP:  3.9;
ML: ±3.0; DV:  3.0 (Paxinos and Watson, 2004). Animals
were allowed 5–7 days of recovery before any experimental
manipulation.
For intracerebral infusions, 30-G needles connected to
Hamilton syringes were used. The infusions were always
bilateral, with volume infusions of 1ml per side. The needle
was left in place for an additional minute after infusion to
allow diffusion and to prevent reflux. The vehicle used in
each case corresponds to the solution in which the
respective drug was dissolved (see Drugs section above).
The doses used for each compound were as follows: 1 mg/ml
for quinpirole and SKF 83822, 1.5 mg/ml for SCH 23390 and
eticlopride, 10 mg/ml for SKF 83959, and 12.5 mg/ml for SKF
38393. At the end of each experiment, cannula placement
was verified by infusion of 1 ml of methylene blue and
histological analysis. Only the behavioral data of animals
with a correct placement of cannulae were included in the
study.
In Vivo Microdialysis
Animals were connected to the microdialysis systems
the evening previous to the microdialysis experiment. The
blocker of each guide cannula was removed and the
microdialysis probe (CMA 11, 1 mm membrane length;
CMA) was inserted and secured in place. Probes were
connected to the microdialysis pump (CMA/100; CMA) with
FEP tubing through a two-channel swivel and were perfused
overnight with an artificial cerebrospinal fluid, at a flow rate
of 0.3 ml/min. Next morning, the flow rate was increased
to 0.6 ml/min, and after 1 h of equilibration, a series of four
30-min baseline samples were collected. Then, animals were
intraperitoneally injected with either saline or cocaine
(20 mg/kg) and confined to the corresponding side of a
three-compartment apparatus (see Behavioral training and
testing section below) during 30 min. They were returned to
their home cage afterwards. Microdialysis samples were
collected every hour during a 24-h period. Acetic acid
(20 mM, 6 ml) was added to the vials where samples were
collected to avoid dopamine degradation.
Biochemical Analysis of Microdialysis Samples
Dialysate dopamine concentrations were analyzed using
high-performance liquid chromatography (HPLC) with
electrochemical detection. Aliquots from dialysate samples
(15 ml) were injected into an Eicom HTEC-500 HPLC system
with an integrated amperometric detector, consisting a PP-
ODS HPLC column (30 4.6 mm2, inner diameter, C-18,
2 mm particulate silica gel) and an HTEC-500 pump (Eicom,
San Diego, CA). The mobile phase consisted of 100 mM
NaH2PO4, 1.3 mM EDTA, 2.0 mM decane-1-sulfonate, and
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1% MeOH, pH 6.0, resulting in a retention time of 2.2–
2.5 min at a pump rate of 0.5 ml/min. Applied potential was
set at þ 450 mV vs Ag/AgCl.
Western Blot Assays
Three different conditions were analyzed: (1) biochemical
profiles of BDNF, p-TrkB and p-ERK1/2 12 h after cocaine
(or saline in the case of controls) injection in one-trial
training; (2) biochemical profiles of BDNF and p-TrkB 12 h
after the last injection of cocaine (or saline in the case
of controls) in three-trial training; and (3) biochemical
profiles of BDNF and p-ERK1/2 after the infusion of the
D1R antagonist SCH 23390 in the dorsal hippocampus. The
dopaminergic antagonist was infused 11.5 h after the
injection of cocaine in one-trial training. Thirty minutes
later, animals were killed; the dorsal hippocampi were
dissected and rapidly homogenized in ice-chilled buffer.
Samples of homogenates (10 mg of protein) were subjected
to SDS-PAGE (10 or 15% gels) under reducing conditions.
Proteins were electrotransferred onto PVDF membranes
for 2 h at 100 V at 4 1C for BDNF analysis. For ERK1/2
and p-TrkB analysis, proteins were transferred onto PVDF
membranes overnight at 40 V at 4 1C. Immunoblots were
performed by incubating membranes with antibodies anti-
BDNF (1:1000, sc-546), anti-actin (1:10 000, sc-1615), anti-
phospho-ERK1/2 (1:4000, no. 9101s), anti-ERK1/2 (1:3000,
no. 9102), anti-phospho-TrkB (1:2000, sc-135645), and anti-
TrkB (1:1000, sc-8316). The blots were scanned in a Storm
845 PhosphorImager (GE Healthcare Life Sciences, Little
Chalfont, UK), and quantifications were carried out with
ImageQuant software (GE Healthcare Life Sciences).
Behavioral Training and Testing
Conditioning. Place conditioning was carried out in
three-compartment chambers; the center compartment
was a short connecting passageway between the condition-
ing chambers in which the animals were placed after drug
injections. One conditioning compartment had black walls
(white squares pattern, grid floor) and the other had white
walls (black lines pattern, perforated floor); the connecting
passage was gray (no pattern, smooth floor). The experi-
ments consisted of three phases: a pretest phase in which
the animals were allowed to explore the entire apparatus for
15 min, a conditioning phase in which they were restricted
to one side of the chamber after saline intraperitoneal
injections and, on alternate days, the other side of the
chamber after saline, cocaine, or LiCl injections, and a test
phase in which they were allowed to explore the open
apparatus again in a drug-free state. During the pretest
phase, if an animal failed to spend at least 90 s in each
compartment, it was excluded from the study. Five out of
954 animals were excluded for this reason.
In the one-trial version of the cocaine conditioning
paradigm, the animals were given an intraperitoneal saline
injection before placement in the initially preferred dark
chamber for 30 min on the first conditioning day and were
given an intraperitoneal cocaine injection before placement
in the initially non-preferred white chamber for 30 min
on the following day. Saline intraperitoneal injections
were given in both compartments for control groups. The
one-trial version was used to establish a weak memory for
the cocaine-chamber association in experiments designed to
assess the effects of treatments designed to increase
memory persistence; the procedure was repeated two times
more in a three-trial version to establish a stronger memory
for the same association in experiments designed to
assess treatments that might decrease memory persistence.
Cocaine doses of 10, 15, or 20 mg/kg were used for the dose–
response experiment, and 20 mg/kg was used for the
remaining experiments. An increase in time spent in the
cocaine-associated chamber after conditioning was taken as
a reflection of the known rewarding properties of cocaine at
this dose (Busse and Riley, 2004; dela Cruz et al, 2009;
Crooks et al, 2010).
In the place conditioning studies with LiCl, the one-trial
version was used. On the first day, the animals were given
intraperitoneal saline and placed in the initially non-
preferred white chamber for 60 min; on the next day, the
animals were given intraperitoneal saline or LiCl (150 mg/kg)
and placed in the initially preferred black compartment for
60 min. In each case, the animals were given open access to
the entire apparatus on the day following the last condition-
ing day; this phase was identical to the pretest: animals in a
drug-free state were left to explore the entire apparatus
during 15 min and the time spent in each compartment was
recorded. A decrease in time spent in the LiCl-associated
chamber after conditioning was taken as a reflection of the
known aversive properties of LiCl at this dose (Tenk et al,
2005).
Supplementary Table 1 shows the mean pre- and
postconditioning times spent in the compartment asso-
ciated with cocaine or LiCl for each of the main results in
this study.
In experiments where intracerebral infusions were
performed, the infusion time was always 12 h after
conditioning. Animals were infused and returned immedi-
ately to their home cages. They were never exposed to
the testing apparatus during or after the infusion procedure.
When a three-trial training protocol was used, the
dopaminergic drugs were infused 12 h after each condition-
ing session with either cocaine or LiCl.
Statistical Analyses
Data were presented as a score in s: time spent in the
drug-associated compartment during the test minus time
spent in the to-be drug-associated compartment during the
pretest. Results are presented as mean±SEM. For beha-
vioral and biochemical data, results were analyzed using a
Student’s t-test in the case where two groups were to be
compared and using a multifactorial analysis of variance
(MANOVA) with cocaine/LiCl (saline vs cocaine/LiCl), dose
(10, 15, or 20 mg/kg), place (home cage vs conditioning
apparatus), time of testing (24 h, and 7 or 14 days), and
challenge (vehicle vs dopaminergic agents) as between-
subject factors, in the case where more than two groups
were to be compared. For significant overall interactions,
further analyses of partial interactions were carried out.
Post hoc analyses were performed with Newman–Keuls test
when the initial p-value was significant. A result was
considered significant if po0.05. All data were analyzed
using Statistica software (Statsoft, Paris, France).
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We first established conditioning parameters that would
result in long-lasting (7 days or more) or short-lasting (24 h
but not 7 days) increases in time spent in the cocaine-
associated chamber using independent animal groups.
Increased times in the cocaine-associated chamber were
seen in rats trained with a single injection (20 mg/kg) and
tested 1 day but not 7 or 14 days after the conditioning trial
(Figure 1a, main effect of cocaine: F(1,58)¼ 31.94, po0.001;
main effect of dose: F(2,58)¼ 0.85, p¼ 0.43, NS; cocaine
dose: F(2,58)¼ 3.70, po0.05; Figure 1b, main effect of
cocaine: F(1,44)¼ 2.05, p¼ 0.16, NS; main effect of time:
F(2,44)¼ 0.40, p¼ 0.67, NS; cocaine time: F(2,44)¼ 4.24,
po0.05). The reversed order of injections of cocaine and
saline gave similar results (Supplementary Figure S1a;
po0.05). Rats given two cocaine training days also showed
an increase in time spent in the cocaine-associated chamber
when tested (1 day but not 7 days) after conditioning
(Supplementary Figure S1b; p¼ 0.18). Independent groups
of rats given three cocaine–chamber pairings showed
increased time in the cocaine-associated chamber when
tested 7, 14, or 21 days after training (Figure 1c, main effect
of cocaine: F(1,62)¼ 27.74, po0.001; main effect of time:
F(3,62)¼ 0.83, p¼ 0.48, NS; cocaine time: F(3,62)¼ 4.43,
po0.05). We subsequently used the single pairing condition
to establish weakly persistent memory and the three-pairing
condition to establish stronger, more persistent memory for
the cocaine–chamber association.
To determine the effects of dorsal hippocampal dopamine
receptor activation on the late post-training consolidation of
the memory for the cocaine–chamber association, we
microinjected dopamine receptor agonists or antagonists
into the dorsal hippocampus 12 h after one- or three-trial
training and tested for retention 24 h or 7 days later (see
Supplementary Figure S2 to check for the location and
extension of the infusions). Rats tested 24 h after one-trial
training showed normal retention following bilateral hippo-
campal microinjections of either the D1R agonist SKF 38393
or the D1R antagonist SCH 23390 (Figure 1d, main effect of
cocaine: F(1,31)¼ 16.54, po0.001; main effect of challenge:
F(1,31)¼ 2.12, p¼ 0.16, NS; cocaine challenge: F(1,31)¼ 0.04,
p¼ 0.84, NS; Figure 1f, main effect of cocaine: F(1,62)¼ 23.87,
po0.001; main effect of challenge: F(1,62)¼ 3.69, p¼ 0.06, NS;
cocaine challenge: F(1,62)¼ 0.04, p¼ 0.84, NS). The dopa-
mine D1R agonist failed to modify the retention of the
cocaine–chamber association when tested 7 days after
training (Figure 1e, main effect of cocaine: F(1,40)¼ 0.34,
p¼ 0.57, NS; main effect of challenge: F(1,40)¼ 0.009,
p¼ 0.93, NS; cocainechallenge: F(1,40)¼ 0.05, p¼ 0.82,
Figure 1 Temporal duration and dopaminergic modulation of the persistence of a short-lasting cocaine-associated memory. (a) Three doses of cocaine
were tested. The dose of 20 mg/kg induced a significant retention of the memory for cocaine–place association when tested 24 h after a one-trial training
(n¼ 5–21 per group). Therefore, this dose was used in all the remaining approach experiments. (b) A weak (one-trial training) memory for the cocaine–
place association was retained for 24 h but not for 7 or 14 days (n¼ 7–11 per group). (c) A strong (three-trial training) memory for the cocaine–place
association was retained for at least 21 days (n¼ 8–10 per group). Asterisks indicate significant differences between cocaine-injected animals and its
corresponding saline controls (Newman–Keuls, *po0.05; **po0.01). (d–g) Effects of D1-type dopamine agonist (SKF 38393) or antagonist (SCH 23390)
injections—given 12 h after the training trial—on the persistence of the memory for cocaine–place associations established by one-trial training. (d) The D1-
type agonist had no effect on the 24 h memory for cocaine–place associations established by one-trial training (n¼ 8–10 per group). (e) The D1-type agonist
had no effect on the persistence of the memory for cocaine–place associations when tested at 7 days after one-trial training (n¼ 10–12 per group). (f) The
D1-type antagonist had no effect on the 24 h memory for cocaine–place associations established by one-trial training (n¼ 16–17 per group). (g) The D1-
type antagonist prolonged the duration of the memory for cocaine–place associations after one-trial training (n¼ 11–14 per group). Post hoc analyses
demonstrated that the group conditioned with cocaine, infused with SCH 23390 12 h later, and tested at 7 days showed a higher score when compared
with the other groups (Newman–Keuls, **po0.01). Asterisks upon bracket indicate a significant difference between saline- and cocaine-injected animals,
collapsed across intracerebral infusion treatments (Newman–Keuls, *po0.05; **po0.01). Coc, cocaine; Sal, saline; Veh, vehicle.
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NS). However, treatment with the D1R antagonist unexpect-
edly extended retention of the association to 7 days
after one-trial training (Figure 1g, main effect of cocaine:
F(1,47)¼ 4.64, po0.05; main effect of challenge: F(1,47)¼ 4.33,
po0.05; cocaine challenge: F(1,47)¼ 7.60, po0.01).
We next determined the effects of the same treatments on
the persistence of the stronger memory established with the
three-trial training paradigm. As in the case of the short-
lasting cocaine-associated memory, neither the D1R
antagonist nor the D1R agonist, given 12 h after training,
affected retention as tested 24 h after training (Figure 2a,
main effect of cocaine: F(1,35)¼ 28.69, po0.001; main effect
of challenge: F(1,35)¼ 0.24, p¼ 0.63, NS; cocaine challenge:
F(1,35)¼ 0.73, p¼ 0.40, NS; Figure 2c, main effect of cocaine:
F(1,31)¼ 28.18, po0.001; main effect of challenge: F(1,31)¼
0.11, p¼ 0.74, NS; cocaine challenge: F(1,31)¼ 0.48,
p¼ 0.49, NS). The D1R antagonist also failed to affect reten-
tion as tested at 7 days (Figure 2d, main effect of cocaine:
F(1,53)¼ 19.96, po0.001; main effect of challenge: F(1,53)¼
0.03, p¼ 0.85, NS; cocaine challenge: F(1,53)¼ 0.04,
p¼ 0.85, NS). Conversely, when the D1R agonist was
administered during the three training trials, the persistence
of a normally long-lasting cocaine-associated memory was
abolished (Figure 2b, main effect of cocaine: F(1,31)¼ 7.44,
po0.05; main effect of challenge: F(1,31)¼ 5.65, po0.05;
cocaine challenge: F(1,31)¼ 4.25, po0.05). Interestingly,
the D1R agonist was ineffective in three cases where the
cannula placement was asymmetrical and injections did not
reach the dorsal hippocampus or reached it on one side
only (Supplementary Figure S3).
Neither the D2-type dopamine receptor agonist quinpirole
(1mg per side; main effect of cocaine: F(1,41)¼ 2.23, p¼ 0.14,
NS; main effect of challenge: F(1,41)¼ 0.0004, p¼ 0.98, NS;
cocaine challenge: F(1,41)¼ 0.06, p¼ 0.80, NS) nor the
D2-type dopamine receptor antagonist eticlopride (1.5mg
per side; main effect of cocaine: F(1,31)¼ 1.03, p¼ 0.32, NS;
main effect of challenge: F(1,31)¼ 0.04, p¼ 0.83, NS; cocaine
challenge: F(1,31)¼ 0.13, p¼ 0.72, NS) affected the persistence
of the weak cocaine-associated memory (Supplementary
Figure S4).
To gain better insight on the molecular mechanisms
underlying the persistence of cocaine-associated memories,
we next used agonists for D1Rs that are selectively coupled
to different intracellular messenger cascades (Undieh,
2010). Whereas the adenylyl cyclase (AC)-selective agonist
SKF 83822 given 12 h after three-trial training had no effect
on retention tested 7 days after training (Figure 3a, main
effect of cocaine: F(1,35)¼ 12.16, po0.01; main effect of
challenge: F(1,35)¼ 1.31, p¼ 0.26, NS; cocaine challenge:
F(1,35)¼ 0.07, p¼ 0.79, NS), the phospholipase C (PLC)-
coupled agonist SKF 83959 significantly decreased retention
at the same time-point (Figure 3b, main effect of cocaine:
F(1,26)¼ 12.40, po0.01; main effect of challenge: F(1,26)¼
8.33, po0.01; cocaine challenge: F(1,26)¼ 5.72, po0.05).
To further investigate the hypothesis that persistent
cocaine-associated memories depend on D1Rs not coupled
to AC, we measured the expression of BDNF, a downstream
component of D1Rs/AC/PKA/BDNF/ERK pathway known
to be elevated in the dorsal hippocampus 12 h after training
in long-lasting fear memories (Bekinschtein et al, 2007;
Rossato et al, 2009). When BDNF levels were measured 12 h
after training, no differences were observed either in
animals subjected to the one-trial (Figure 3c, main effect
of cocaine: F(1,16)¼ 0.88, p¼ 0.36, NS; main effect of place:
F(1,16)¼ 0.24, p¼ 0.63, NS; cocaine place: F(1,16)¼ 0.26,
p¼ 0.61, NS) or to the three-trial (Figure 3d, main effect of
cocaine: F(1,10)¼ 0.0003, p¼ 0.99, NS; main effect of place:
F(1,10)¼ 2.15, p¼ 0.17, NS; cocaine place: F(1,10)¼ 0.89,
p¼ 0.37, NS) training. Furthermore, BDNF levels were not
affected by dorsal hippocampal injections of the D1R
antagonist SCH 23390, a treatment that improved the
persistence of a weak cocaine-related memory (Figure 3e,
main effect of group: F(2,42)¼ 0.99, p¼ 0.38, NS). In
addition, no alterations were observed in the phosphoryla-
tion state of TrkB, or in the activation of ERK1/2, which are
downstream steps of BDNF-induced memory persistence in
the case of fear memories (Supplementary Figure S5).
It was not expected that dopamine agonists would inhibit
the late-phase of cocaine-associated memory consolidation
because dopamine is known to be necessary for promoting
Figure 2 Dopaminergic modulation of the persistence of a long-lasting cocaine-associated memory. Effects of D1-type dopamine agonist (SKF 38393) or
antagonist (SCH 23390) injections—given 12 h after the training trial—on the persistence of the memory for cocaine–place associations established by 3-
trial training. (a) The D1-type agonist (SKF 38393) had no effect on the 24 h memory for cocaine–place associations established by three-trial training (n¼ 9–
10 per group). (b) Treatment with the D1-type agonist (SKF 38393) attenuated the 7-day persistence of the memory for cocaine–place associations
established by three-trial training (n¼ 7–10 per group). (c) The D1-type antagonist (SCH 23390) had no effect on the 24 h memory for cocaine–place
associations established by three-trial training (n¼ 8–10 per group). (d) The D1-type antagonist (SCH 23390) had no effect on the persistence of the
memory for cocaine–place associations when tested at 7 days after three-trial training (n¼ 13–15 per group). Post hoc analyses demonstrated that the group
conditioned with cocaine, infused with SKF 38393 12 h later, and tested at 7 days showed a higher score when compared with the other groups (Newman–
Keuls, **po0.01). Asterisks upon bracket indicate a significant difference between saline and cocaine-injected animals, collapsed across intracerebral infusion
treatments (Newman–Keuls, **po0.01; ***po0.001). Coc, cocaine; Sal, saline; Veh, vehicle.
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the late-phase of aversive memory consolidation in a
step-down avoidance task (Rossato et al, 2009). To
determine the role of dorsal hippocampal dopamine in an
avoidance context, we substituted the rewarding agent
cocaine by an aversive agent. Here we used LiCl, an aversive
agent known to be capable of establishing taste and place
avoidance (Nachman, 1963; Tenk et al, 2005) as our
unconditioned stimulus. In our place-conditioning para-
digm, it had the opposite effect of cocaine; where rats
increased the time they spent in the cocaine-associated
chamber, other independent group of rats decreased the
time spent in the LiCl-associated chamber. This effect was
seen 24 h but not 7 days after training (Supplementary
Figure S6; po0.05). Bilateral dorsal hippocampal infusions
of the D1R agonist SKF 38393 given 12 h after training
facilitated the persistence of the LiCl-associated memory,
which remained strong 7 days after training (Figure 4,
main effect of LiCl: F(1,30)¼ 5.98, po0.05; main effect
of challenge: F(1,30)¼ 13.81, po0.001; LiCl challenge:
F(1,30)¼ 4.55, po0.05). Thus, late post-training activation
of hippocampal D1Rs had opposite effects on the persis-
tence of the memory for learned cocaine–context and
LiCl–context associations, increasing the persistence of the
memory for the association between LiCl and the place
where it was given and decreasing the persistence of the
memory for the association between cocaine and the place
where it was given.
The dopamine-dependent potentiation of late-phase
memory consolidation through PLC-coupled D1Rs might
require only normal baseline levels of hippocampal
Figure 3 Persistence of cocaine-related memories is regulated by dopaminergic receptors coupled to phospholipase C (PLC) cascade and is not
mediated by brain-derived neurotrophic factor (BDNF). (a) Delayed (12 h after conditioning trial) infusion of the adenylyl cyclase (AC)-selective D1-type
agonist SKF 83822 had no effect on the 7-day retention of the memory for cocaine–place associations established by three-trial training (n¼ 9–10 per
group). (b) Delayed (12 h after conditioning trial) infusion of the PLC-selective D1-type agonist SKF 83959 significantly attenuated 7-day retention of the
memory for cocaine–place associations established by three-trial training (n¼ 7–9 per group). Post hoc analyses demonstrated that the group conditioned
with cocaine, infused with SKF 83959 12 h later, and tested at 7 days showed a higher score when compared with the other groups (Newman–Keuls,
*po0.05). Asterisks upon bracket indicate a significant difference between saline- and cocaine-injected animals, collapsed across intracerebral infusion
treatments (Newman–Keuls, **po0.01). (c–e) Dorsal hippocampal levels of BDNF of animals administered either saline or 20 mg/kg cocaine. Animals were
injected and returned to their home cages (HC groups) or were conditioned as described (C groups). In all the figures, control group is represented by
animals injected with saline and left undisturbed in their home cages (Sal/HC groups). (c) Levels of dorsal hippocampal BDNF measured at 12 h after one-
trial training. BDNF levels did not vary across treatments (n¼ 5 per group). (d) Levels of dorsal hippocampal BDNF measured at 12 h after three-trial
training. BDNF levels did not vary across treatments (n¼ 3–4 per group). (e) SCH 23390 administration did not modify the dorsal hippocampal levels of
BDNF measured at 12 h after one-trial training. Animals were conditioned with either saline or cocaine; 11.5 h later they were infused with SCH 23390 or its
vehicle and were killed 30 min later (n¼ 15 per group). Coc, cocaine; Sal, saline; Veh, vehicle.
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dopamine. To determine if there are normal or fluctuating
levels of dopamine at the time when dopamine inhibits late-
phase memory consolidation for cocaine–place associa-
tions, we used microdialysis to monitor dorsal hippocampal
dopamine levels over the 24 h after cocaine treatment. Here,
we used the one-trial paradigm. After a large but variable
(and thus statistically unreliable) surge following the
training injection of cocaine, dopamine levels returned to
a stable baseline within about 5 h, but increased again for a
period of 4 h starting 13 h after the training session
(Figure 5). The increase began 3 h after the onset of the
light phase of the light–dark cycle, at a time when striatal
dopamine levels normally become depressed (Castañeda
et al, 2004); thus, it was not obviously time-locked to the
light change. The cocaine-injected animals showed a reliable
increase in approach to the cocaine-associated chamber
when tested 4 h after the completion of the microdialysis
experiments (Supplementary Figure S7; po0.05).
DISCUSSION
The present findings have two important implications. First,
we report for the first time a role for dopamine in the dorsal
hippocampus on the long-term storage for a cocaine-
associated memory, an influence on memory storage that
develops long after the elevation in dopamine levels caused
by cocaine itself. Second, we report opposite effects of
hippocampal dopamine actions on the memory for the
association of neutral environmental place cues with the
rewarding drug cocaine on the one hand or the memory for
the association of the environmental place cues with the
aversive drug LiCl on the other; stimulating dorsal
hippocampal D1-type dopamine receptors decreased the
persistence of the memory for a cocaine–place association,
but increased the persistence of LiCl–place memory.
The persistence of a weak cocaine-conditioned memory
was enhanced by blocking dorsal hippocampus D1Rs 12 h
after conditioning; it was attenuated by stimulating these
receptors. The effects were not due to enhancing or
blocking the impact of the acute extracellular dopamine
elevation resulting from cocaine’s blockade of the dopamine
transporter, as dopamine levels had returned to normal
within 5–6 h of cocaine injection. However, there was a 4-h
surge in extracellular dopamine concentration that began
about 13 h after the cocaine injection, and there was neither
a pharmacological treatment nor a change in environmental
stimulus conditions at that time. This surge in dopamine
levels was presumably caused by an increase in dopamine
cells firing in the VTA, and the cause of such an increase is a
matter for future investigation. That microinjection of D1R
agonists attenuated retention of the cocaine-associated
memory suggests that the increase in dopamine 13 h after
cocaine place conditioning is itself a limiting factor in the
persistence of cocaine-associated memories.
This observation is surprising in that it is inconsistent
with what is known of the role of dorsal hippocampal
dopamine in late-phase consolidation of instrumental
avoidance memories (Rossato et al, 2009). Indeed,
the effects of dopamine receptor manipulations in our task
were opposite to those previously reported for a step-down
avoidance task; in the avoidance task, dopamine agonists
administered to the dorsal hippocampus 12 h (but not 0
or 9 h) after conditioning promoted late-stage memory
consolidation, whereas dopamine antagonists restricted it
(Rossato et al, 2009). To be sure that our finding was not
unique to our place-conditioning paradigm, we confirmed
Figure 4 Effects of D1-type dopamine agonist (SKF 38393) on the
persistence of the memory for one-trial LiCl–place associations. Infusion of
the D1-type agonist (SKF 38393) enhanced the retention of the 7-day
memory for the place associations induced by LiCl (n¼ 7–9). Asterisk
indicates significant post hoc comparisons (Newman–Keuls, *po0.05). LiCl,
lithium chloride; Sal, saline; Veh, vehicle.
Figure 5 Dopamine (DA) fluctuations in microdialysis samples from the
dorsal hippocampus of animals following one-trial training for cocaine–place
associations. Cocaine or saline was given at the arrow after the baseline
period (B) and hourly samples were taken for the next 24 h. The inset
shows the results of four baseline samples pooled together. There were no
significant differences in baseline between the two groups (n¼ 7 per group;
Student’s t-test, t(12)¼  0.31; p¼ 0.76). There were no significant
differences in DA measurements between groups during the first 12-h
period of the experiment (main effect of cocaine: F(1,12)¼ 1.72; p¼ 0.21,
NS; main effect of time: F(11,132)¼ 1.30; p¼ 0.23, NS; cocaine time
interaction: F(11,132)¼ 0.69; p¼ 0.74, NS). However, during the second
12-h period, there was a significant main effect of time, F(11,132)¼ 2.04;
p¼ 0.03 and a significant cocaine time interaction, F(11,132)¼ 4.17;
p¼ 0.00003. Asterisks indicate significant post hoc comparisons (Newman–
Keuls, **po0.01; ***po0.001). The horizontal bar in the bottom of the
figure indicates the dark–light cycle (black: lights out).
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that a D1R agonist facilitates late-phase avoidance memory
persistence in a paradigm similar to ours, but using an
aversive rather than a rewarding stimulus. Our LiCl con-
ditioning task involved the same equipment and protocol as
was used for cocaine conditioning, but using the aversive
agent LiCl rather than the appetitive agent cocaine, as the
unconditioned stimulus. Our results thus suggest opposite
roles for dorsal hippocampal dopamine in the late phase of
LTM storage of memories associated with rewarding and
aversive stimuli.
The obtained results suggest that the dopaminergic agents
used involved actions at a given subtype of the D1-like
dopamine receptors family. D1-like receptors are subdi-
vided into D1 and D5 subtypes (Monsma et al, 1990;
Sunahara et al, 1991), each of which is expressed in
hippocampal neurons. The D5 subtype, presumably the one
subtype coupled to PLC (Sahu et al, 2009; Undieh, 2010), is
densely expressed in the hippocampus (Laurier et al, 1994)
and has a 10-fold higher affinity for DA than does the D1
subtype (Sunahara et al, 1991). We found that SKF 83959
(thought to act specifically at the D5 receptor because it
induces the selective activation of PLC intracellular cascade;
Undie et al, 1994) had the inhibitory effect we saw with the
more generic agonist, whereas SKF 83822, which induces
activation of the AC intracellular cascade (O’Sullivan et al,
2004), failed to do so. These data suggest that the D5
subtype is important for modulating the persistence of
contextual memories associated with the rewarding drug
cocaine, whereas the D1 subtype is important for modulat-
ing the persistence of contextual memories associated with
the aversive agent LiCl (present study), along with those
associated with the aversive effects of painful footshock
(Rossato et al, 2009). Consistent with this suggestion, the
levels of BDNF and the activation of TrkB and ERK1/2,
which are downstream effectors of D1Rs coupled to AC in
controlling the persistence of an aversive memory (Rossato
et al, 2009), were unchanged 12 h after cocaine-context
conditioning.
These and earlier studies involving step-down avoidance
(Rossato et al, 2009) make it clear that dopamine-dependent
events taking place in the dorsal hippocampus around 12 h
after a learning experience can enhance or limit the
persistence of the memory for that experience (Supple-
mentary Figure S8). One possibility is that dopamine is
enhancing or inhibiting the continuing process of long-term
storage of the original memory for the learning event.
Another possibility to consider is whether dopamine is
enhancing or inhibiting the reconsolidation of a reactivated
trace. Consistent with this latter view is that the dopamine
system, at least, is clearly reactivated at about this time.
Against that view, however, are several facts. First, there is
no obvious source of reactivation of the initial memory; the
animals were not exposed to the contextual stimuli
associated with the learning experience until they were
tested 24 h or more hours later. Second, the effects of
dopamine manipulations were time-locked to the original
training; when given in the same way with the same
attendant handling and lab activity at earlier times, the
dopamine manipulations are ineffective (Rossato et al,
2009). Also seemingly inconsistent with any hypothesis
involving spontaneous reactivation and reconsolidation
during subsequent sleep is the fact that D1R activation
had opposite effects on the duration of memories for place
associations with rewarding and aversive stimuli.
The fact that the memory for a cocaine–place association
is still labile 12 h after the event has potential implications
for addiction therapy. Addicts who continue taking drug
even after becoming tolerant to them often report that they
are ‘chasing the remembered high’; thus, the memory for an
early drug experience can have a significant role in
subsequent drug-seeking. The fact that cocaine-associated
memories are still labile and that their persistence can still
be affected several hours after the experience should
encourage recent suggestions (Mihindou et al, 2011; Xue
et al, 2012; Wang et al, 2013) that the memory traces of drug
experience itself may offer useful new targets for addiction
treatment.
FUNDING AND DISCLOSURE
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
We gratefully acknowledge Dr Gustavo Murer and Verardo
y Cı́a. laboratory for their kind donation of quinpirole and
cocaine hydrochloride, respectively. We thank Catherine
Schweppe, Fernando Garagoli, Eduardo Gigante, and
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